02257 SIRNAOMICS-B
- 7.650
- +0.390+5.37%
SIRNAOMICS-B News
Express News | CITIC Construction Investment: The national biotechnology and biomanfacture action plan is expected to be introduced in the near future, and the subsequent implementation of the policy is worth looking forward to
Shengnuo Pharmaceutical-B (02257): Wang Yongxiang was appointed as Executive Director
Shengnuo Pharmaceutical-B (02257) announced that Dr. Wang Yongxiang was appointed as an executive director from May 1, 2024...
Hong Kong pharmaceutical stocks rose, and Shengnuo Pharmaceutical-B rose more than 16%
Hong Kong pharmaceutical stocks rose; Shengnuo Pharmaceutical-B rose more than 16%, Zaiding Pharmaceuticals rose nearly 10%, and BeiGene Shenzhou rose more than 6%.
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
聖諾醫藥-B：2023年度報告
Zhitong Hong Kong Stock Short Position Statement Statistics|April 26
Zhitong Hong Kong Stock Short Position Statement | April 26
Statistics on changes in the share of Zhitong Hong Kong Stock Connect | April 26
According to data disclosed on April 25, 2024, Shengnuo Pharmaceutical-B (02257.HK), Tiger Pharmaceuticals (03347.HK), and Peer Hunting (06100.HK) Hong Kong Stock Connect held the largest share value added, increasing 0.58%, 0.47%, and 0.39% respectively; China Alcoa International (02068.HK), Luoyang Yiye (03993.HK), and Country Garden Services (06098.HK) had the largest share losses, decreasing -0.0.75%, -0.3%, respectively -0.57%.
Sirnaomics Receives US FDA Guidance on Trials for Squamous Cell Carcinoma Treatment
Sirnaomics (HKG:2257) received guidance from the US Food and Drug Administration for the drugmaker's phase 2/3 and phase 3 clinical studies of STP705 for treating squamous cell carcinoma in situ. The
Cash flow is about to run out, and Shengnuo Pharmaceutical-B (02257) is surging only to “trick people”?
The stock price dropped 90% within a year, and the majority shareholders were forced to close their positions last month. At this juncture, the stock price suddenly surged more than 20%, which is probably not a good thing for Shengnuo Pharmaceutical-B (02257). On April 17, Shengnuo Pharmaceutical's stock price opened higher in early trading, reaching a maximum increase of 37.87%. According to the news, Shengnuo Pharmaceutical announced on the same day that the company has obtained a written response from the US FDA's Class C meeting on the requirements of its core product STP705. The company has initiated the required preclinical studies in accordance with FDA guidance recommendations. According to the Zhitong Finance App, the purpose of the Class C conference mentioned above was to obtain F
Hong Kong Stock Afternoon Review | Hang Seng Index and Technology Index fell slightly; chip stocks rose more than 5% in Fudan, Shanghai
Heavy infrastructure stocks generally rose; China Zhongzhi and China Railway rose about 3%; gaming stocks continued to decline, and Galaxy Entertainment fell more than 5%.
Shengnuo Pharmaceutical-B (02257): Further development of STP705 for sirnaomics to treat squamous cell carcinoma in situ obtained specific guidance from the FDA
Shengnuo Pharmaceutical-B (02257) issued an announcement. The company has obtained information from the US Food and Drug Administration (FDA)...
Changes in Hong Kong stocks | Shengnuo Pharmaceutical-B (02257.HK) fell more than 11% in the afternoon to a record low, the company's cash flow is in a hurry, and no products have been commercialized
Shengnuo Pharmaceutical-B (02257.HK) fell more than 11% in the afternoon to a new low. Recently, the stock price has continued to decline, with the biggest drop of more than 93% from its all-time high. As of press release, it fell 11.07% to HK$6.43, with a turnover of HK$16.9093 million.
Changes in Hong Kong stocks | Shengnuo Pharmaceutical-B (02257.HK) fell nearly 5%, directors' salary increases raised questions in the market, and the company's cash flow was urgent
Shengnuo Pharmaceutical-B (02257.HK) fell nearly 5%. As of press release, it was down 4.79% to HK$7.55, with a turnover of HK$4.724,200.
Express News | CEO of Shengnuo Pharmaceuticals: There is no risk that the shares held will be forcibly sold
Sirnaomics Announces 2023 Full Year Results
Focus on integrating resources into leading development projects to promote clinical research on the core products STP705, STP707 and STP122G Hong Kong, Germany City, Maryland, and Suzhou, China, March 28, 2024/PRNewswire/ -- Sirnaomics Ltd. (the “Company”, together with its subsidiaries, collectively referred to as “SirnaOmics” or the “Group”; stock code: 2257), an industry-leading biopharmaceutical company focused on developing and creating RNAi drugs, announced the year ended December 31, 2023 Review of (“this year”)
Intraday quick overview | The three major indices rose sharply, the Keji Index rose more than 2%, Bilibili rose nearly 8%, and JD and Meituan rose more than 5%
Biotech stocks rose, with Yao Ming Biotech up more than 6%, Genting Xinyao by more than 5%, Kingsray Biotech by more than 4%, and BeiGene Shenzhou by nearly 2%; Apple concept stocks generally rose, Ruisheng Technology and Gaowei Electronics by about 5%, and Shunyu Optics and Qiutai Technology by about 2%.
Shengnuo Pharmaceutical-B (02257) announced annual results, loss attributable to shareholders of US$786.91 million narrowed 10.88% year-on-year
Shengnuo Pharmaceutical-B (02257) announced its annual results for the year ended December 31, 2023. The group...
SIRNAOMICS-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Dai Xiaochang sold 2,067 million common shares of Shengnuo Pharmaceutical-B (02257.HK), worth approximately HK$20.28 million
On March 25, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on March 25, Dai Xiaochang sold $2,067 million shares of $Shengnuo Pharmaceutical-B (02257.HK) at an average price of HK$9.6869 per share on March 21, worth approximately HK$20.228 million. After the sale, Dai Xiaochang's latest shareholding was 3.52 million shares, and the good position ratio dropped from 6.38% to 4.02%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their shares in listed companies
Analysis
Price Target
No Data
